The Comparison of BCG Maintenance Treatments in High Grade Bladder Tumor Patient

Aim: We aimed to compare recurrense, progression and side effects with maintenance full and half dose BCG treatment in high grade bladder tumor patients in this study. Material and Method: We include the patients who had undergone transurethral resection of bladder tumor(TUR-BT) between 2006 June %u2013 2009 December and histopathological examination 71 of them revealed high risk; carsinoma in situ (CIS) T1G3 and multifocal T1G2.After applying the standart SWOG BCG induction regimen they are divided into two randomised group.We planned to give fully maintenance BCG dose for 32 of 71 people while 39 took half dose during therapy. Results: The amount of 17 patients have recurrent disease, eight of them from fully dose group and nine from half dose group.There%u2019s no significant difference (p=1.000) between two groups. Progression has occured in 12 patients of whom seven from half dose and five from fully dose group. No statistical significance found (p=1.000). The most common side effects dysuria and cystitis were more associated with fully dose group with statistically significant evidence while the other side effects had no meaningful difference. Discussion: Intravesical BCG treatment is considered to be very effective treatment to prevent recurrense and progression intermediate and especially in high grade bladder tumors. But it is still controversial how long and how frequent intravesical instillations have to be given. Although the side effects have been seen to be the most common causes of stopping treatment, the new studies may help to find optimum dose and treatment for bladder cancer